Red blood cell distribution width and the risk of being in poor glycemic control among patients with established type 2 diabetes

Therapeutics and Clinical Risk Management
Yaqi YinYiming Mu

Abstract

The red cell distribution width (RDW) has been shown to be associated with the incidence and complications of type 2 diabetes (T2D). However, the relevance of RDW with the risk of being in poor glycemic control among patients with established T2D is largely overlooked. A total of 702 T2D participants from the REACTION study were enrolled in this study. Blood routine index, fasting plasma glucose, hemoglobin A1c and lipid profile data were available for all of the enrolled population. The univariate logistic analysis revealed a significant association between RDW and the risk of being in poor glycemic control among T2D subjects with an odds ratio (OR) and a 95% confidence interval (CI) of 0.5 and 0.3-0.8, respectively, for the fourth vs the first quartile of RDW. The association strengthened after multivariable adjustment (OR [95% CI]: 0.3 [0.2-0.7]). Interaction and stratified analyses indicated that this association was seen only among T2D subjects with lower body mass index and/or serum lipid levels. T2D patients with higher RDW had significantly lower risk of being in poor glycemic control. RDW may contribute to risk assessment for T2D individuals at risk of being in poor glycemic control.

Citations

May 28, 2020·Frontiers in Physiology·Anna BogdanovaAsya Makhro
Feb 17, 2021·Journal of Cellular and Molecular Medicine·Maria Aparecida KnychalaNilson Penha-Silva
May 29, 2021·International Urology and Nephrology·Tian-Bao HuangXue-Fei Ding
Aug 9, 2021·Journal of Diabetes and Its Complications·Dimitrios TsilingirisStavros Liatis

❮ Previous
Next ❯

Methods Mentioned

BETA
ESR

Software Mentioned

R

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.